DE69738670D1 - Verfahren zur oligomerisation von peptiden - Google Patents

Verfahren zur oligomerisation von peptiden

Info

Publication number
DE69738670D1
DE69738670D1 DE69738670T DE69738670T DE69738670D1 DE 69738670 D1 DE69738670 D1 DE 69738670D1 DE 69738670 T DE69738670 T DE 69738670T DE 69738670 T DE69738670 T DE 69738670T DE 69738670 D1 DE69738670 D1 DE 69738670D1
Authority
DE
Germany
Prior art keywords
oligomerization
peptides
oligomer
oligomerizing
domain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69738670T
Other languages
English (en)
Inventor
Alexey Terskikh
Reto Crameri
Jean-Pierre Mach
Doussal Jean-Marc Le
Andrey Kajava
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Suisse De Recherches Experimentales S Ch
Swiss Institute For Allergy And Asthma Researc Ch
Universite de Lausanne
Original Assignee
INSTITUT SUISSE DE RECHERCHES EXPERIMENTALES SUR LE CANCER ISREC
SWISS INSTITUTE FOR ALLERGY AND ASTHMA RESEARCH
INST SUISSE DE RECH S EXPERIME
SWISS INST FOR ALLERGY AND AST
Novartis AG
Universite de Lausanne
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by INSTITUT SUISSE DE RECHERCHES EXPERIMENTALES SUR LE CANCER ISREC, SWISS INSTITUTE FOR ALLERGY AND ASTHMA RESEARCH, INST SUISSE DE RECH S EXPERIME, SWISS INST FOR ALLERGY AND AST, Novartis AG, Universite de Lausanne filed Critical INSTITUT SUISSE DE RECHERCHES EXPERIMENTALES SUR LE CANCER ISREC
Application granted granted Critical
Publication of DE69738670D1 publication Critical patent/DE69738670D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
DE69738670T 1996-10-28 1997-10-24 Verfahren zur oligomerisation von peptiden Expired - Lifetime DE69738670D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96810719 1996-10-28
PCT/EP1997/005897 WO1998018943A1 (en) 1996-10-28 1997-10-24 Method for the oligomerisation of peptides

Publications (1)

Publication Number Publication Date
DE69738670D1 true DE69738670D1 (de) 2008-06-19

Family

ID=8225734

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69738670T Expired - Lifetime DE69738670D1 (de) 1996-10-28 1997-10-24 Verfahren zur oligomerisation von peptiden

Country Status (7)

Country Link
US (1) US20100105876A1 (de)
EP (1) EP0938571B8 (de)
AT (1) ATE394492T1 (de)
AU (1) AU6909298A (de)
DE (1) DE69738670D1 (de)
ES (1) ES2309999T3 (de)
WO (1) WO1998018943A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6160088A (en) * 1998-07-29 2000-12-12 Sloan-Kettering Institute For Cancer KDEL receptor inhibitors
MXPA01007602A (es) * 1999-02-01 2003-06-24 Beth Israel Hospital Comp/tsp-1, comp/tsp-2 y otras proteinas quimericas..
AU4933200A (en) * 1999-05-14 2000-12-05 Medical Research Council Oligomeric chaperone proteins
AU4770300A (en) * 1999-05-14 2000-12-05 Medical Research Council Protein scaffold and its use to multimerise monomeric polypeptides
EP1373546A4 (de) * 2001-03-06 2005-09-21 Mustapha Abdelouahed Chimäre trägerproteine, zielgerichtete chimäre trägerproteine sowie deren herstellung
EP1456651B1 (de) * 2001-11-30 2008-05-07 National Research Council Of Canada Selbstanordnende moleküle
JP2007527206A (ja) * 2003-04-04 2007-09-27 ユニバーシティ オブ ローザンヌ がん治療のためのペプタボディ
GB2408507B (en) * 2003-10-06 2005-12-14 Proimmune Ltd Chimeric MHC protein and oligomer thereof for specific targeting
GB2409456B (en) * 2003-10-30 2006-01-04 Proimmune Ltd Oligomeric receptor ligand pair member complexes
US7985585B2 (en) 2004-07-09 2011-07-26 Viacyte, Inc. Preprimitive streak and mesendoderm cells
US7625753B2 (en) 2003-12-23 2009-12-01 Cythera, Inc. Expansion of definitive endoderm cells
US8647873B2 (en) 2004-04-27 2014-02-11 Viacyte, Inc. PDX1 expressing endoderm
US20050266554A1 (en) 2004-04-27 2005-12-01 D Amour Kevin A PDX1 expressing endoderm
WO2007059007A2 (en) 2005-11-14 2007-05-24 Cythera, Inc. Markers of definitive endoderm
MX2009009225A (es) 2003-12-23 2009-09-28 Cythera Inc Endodermo definitivo.
EP1791952A4 (de) 2004-08-13 2008-06-11 Univ Georgia Res Found Zusammensetzungen und verfahren zur selbsterneuerung und differenzierung bei menschlichen embryonalen stammzellen
US7989204B2 (en) 2006-04-28 2011-08-02 Viacyte, Inc. Hepatocyte lineage cells
US7695963B2 (en) 2007-09-24 2010-04-13 Cythera, Inc. Methods for increasing definitive endoderm production
AR068767A1 (es) 2007-10-12 2009-12-02 Novartis Ag Anticuerpos contra esclerostina, composiciones y metodos de uso de estos anticuerpos para tratar un trastorno patologico mediado por esclerostina
EA027575B1 (ru) 2008-08-05 2017-08-31 Новартис Аг Антитело или его антигенсвязывающий фрагмент, связывающий человеческий белок с5, содержащая их композиция, нуклеиновая кислота, кодирующая антитело или его антигенсвязывающий фрагмент, содержащие эту кислоту вектор и клетка-хозяин и применение антитела или его антигенсвязывающего фрагмента
CA2753282C (en) 2009-03-10 2017-11-28 Med Discovery Sa Use of serine protease inhibitors in the treatment of neutropenia
WO2010102518A1 (zh) * 2009-03-13 2010-09-16 北京表源生物技术有限公司 一种融合蛋白多聚体
JP5766179B2 (ja) 2009-04-27 2015-08-19 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
WO2011029823A1 (en) 2009-09-09 2011-03-17 Novartis Ag Monoclonal antibody reactive with cd63 when expressed at the surface of degranulated mast cells
ES2692519T3 (es) 2011-07-01 2018-12-04 Novartis Ag Método para tratar trastornos metabólicos
AU2013355414B2 (en) 2012-12-05 2017-02-02 Novartis Ag Compositions and methods for antibodies targeting EPO
CN105960414A (zh) 2013-08-14 2016-09-21 诺华股份有限公司 治疗散发性包涵体肌炎的方法
TW201622746A (zh) 2014-04-24 2016-07-01 諾華公司 改善或加速髖部骨折術後身體復原之方法
AU2018240117A1 (en) 2017-03-24 2019-09-19 Beth Israel Deaconess Medical Center, Inc. Methods for preventing and treating heart disease
WO2018176144A1 (en) * 2017-03-29 2018-10-04 Sunnybrook Research Institute Engineered t-cell modulating molecules and methods of using same
EP3704150A1 (de) * 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG Compbody ein multivalentes zielbindemittel
CN115232205A (zh) * 2022-08-03 2022-10-25 南京京达生物技术有限公司 一种鼠源IgM亚型单克隆抗体纯化方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995026985A1 (en) * 1994-04-05 1995-10-12 Board Of Regents, The University Of Texas System Modified receptors that continuously signal
GB9409768D0 (en) * 1994-05-16 1994-07-06 Medical Res Council Trimerising polypeptides
JPH11508126A (ja) * 1995-05-23 1999-07-21 モルフォシス ゲゼルシャフト ファー プロテインオプティマイルング エムベーハー 多量体タンパク質

Also Published As

Publication number Publication date
ATE394492T1 (de) 2008-05-15
ES2309999T3 (es) 2008-12-16
EP0938571A1 (de) 1999-09-01
WO1998018943A1 (en) 1998-05-07
EP0938571B8 (de) 2008-07-02
US20100105876A1 (en) 2010-04-29
EP0938571B1 (de) 2008-05-07
AU6909298A (en) 1998-05-22

Similar Documents

Publication Publication Date Title
ATE394492T1 (de) Verfahren zur oligomerisation von peptiden
NO964650D0 (no) LAG-3 protein-opplöselige polypeptidfraksjoner, fremgangsmåte for fremstilling, teraupeutisk preparat og anti-idiotype antistoff
DK0934526T3 (da) Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål
ATE137245T1 (de) Synthetische peptide zum in vivo nachweis von thrombosen
DK0724456T3 (da) CD40-Antistoffer
DE69735359D1 (de) System zur auswahl von produkten
DE69733650D1 (de) System zur gleichzeitigen durchführung von mehrfachligandenbindungstests
DE68915258D1 (de) Verfahren zur katalytischen Oligomerisierung von Olefinen.
ATE210683T1 (de) Vernetzungsprodukte von aminogruppen-haltigen biopolymeren
IL130036A0 (en) Survivin a protein that inhibits cellular apoptosis and its modulation
FI960888A (fi) Protokadheriiniproteiineja ja niiden käyttö
DE69703449T2 (de) Neuroaktive peptide
ATE182622T1 (de) Gen des von hippel-lindau (vhl) syndroms und entsprechende cdns und methoden zur detektion von trägern des entsprechenden gens
GR3036782T3 (en) Proteases capable of shedding the soluble TNF-receptor and TNF-R derived peptides and antibodies against the proteases inhibiting the shedding.
DE69738930D1 (de) Methoden zur modulation der melaninsynthese
ATE223481T1 (de) Peptid der löslichen form von acetylcholinesterase mit aktivität als calciumkanalmodulator
ATE329929T1 (de) Dimere des kleeblatt-proteins
DE69607034D1 (de) Pcna bindende substanz
DE69707294T2 (de) Kombinatorisches verfahren zur identifizierung von organometallischen polymerisationskatalysatoren
NO922421D0 (no) Collagenbindende protein, samt fremstilling derav
DE58903571D1 (de) Verfahren zur dimerisierung von hexafluorpropenoxid.
DE3869565D1 (de) Verfahren zur dimerisation von aromatischen halogeniden.
DE68904315D1 (de) Peptide-hemmer von phospholipase a2.
DE59702891D1 (de) Verfahren zur Oligomerisierung von i-Buten
DE69736708D1 (de) Produkt zur proteinstabilisierung von weinen

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: INSTITUT SUISSE DE RECHERCHES EXPERIMENTALES S, CH

Owner name: SWISS INSTITUTE FOR ALLERGY AND ASTHMA RESEARC, CH

Owner name: UNIVERSITY OF LAUSANNE, EPALINGES, CH

8328 Change in the person/name/address of the agent

Representative=s name: PATENTANWAELTE LIPPERT, STACHOW & PARTNER, 51427 B

8364 No opposition during term of opposition